Skip to content

Trimetazidine modified release tablets in Angina and Poor muscle function (TAP): a randomized controlled study

Trimetazidine modified release tablets in Angina and Poor muscle function (TAP):a randomized controlled study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015000
Enrollment
Unknown
Registered
2018-02-27
Start date
2018-03-01
Completion date
Unknown
Last updated
2018-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stable angina

Interventions

TMZ group: A dose of 35mg oral TMZ is administered during 2 times of meal a day besides conventional treatments in TMZ group for 3 months.
Control group:Routine treatment

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. more than 60 years of age; 2. ICF signature confirmed; 3. low HS (<26.0kg for men and <18.0kg for women) or low GS criterion (<0.8m/s) [9-10]; 4. stable angina criterion (a history of Coronary artery disease (CAD) diagnosed by coronary artery angiography, computed tomography angiography or treadmill test and the same cause, nature, location, duration, remission and frequency of angina during past 3 months)

Exclusion criteria

Exclusion criteria: 1. secondary hypertension; 2. secondary poor muscle strength or physical performance, including New York Heart Association class III to IV heart failure; 3. operation in the past 3 months or poor exercise performance caused by neurological diseases, musculoskeletal diseases or pain; 4. liver or renal dysfunction; 5. diagnosed thyroid diseases; 6. diagnosed hematological diseases; 7. diagnosed unhealed tuberculosis or metastatic advanced tumor or malignant tumor discovery less than 5 years; 8. being hypersensitive to TMZ contents or having taken TMZ in the past 3 months; 9. failure of cooperation because of other comorbidities.

Design outcomes

Primary

MeasureTime frame
6-minite walking distance (6MWD) change;

Secondary

MeasureTime frame
handgrip strength;pinch strength;gait speed (GS);Five Times Sit-to-Stand Test (FTSST);;

Countries

China

Contacts

Public ContactLi Xiaoying

Chinese PLA General Hospital

xyli301@foxmail.com+86 010-66876271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 21, 2026